​

Cullinan Therapeutics (CGEM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CGEM Stock Forecast

Cullinan Therapeutics (CGEM) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $31.50, with a high of $38.00 and a low of $28.00. This represents a 375.83% increase from the last price of $6.62.

$5 $12 $19 $26 $33 $40 High: $38 Avg: $31.5 Low: $28 Last Closed Price: $6.62

CGEM Stock Rating

Cullinan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CGEM Price Target Upside V Benchmarks

TypeNameUpside
StockCullinan Therapeutics375.83%
SectorHealthcare Stocks 13.55%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$30.00
Last Closing Price$6.62$6.62$6.62
Upside/Downside--353.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2528---10
Aug, 2518---9
Jul, 2518---9
Jun, 2517---8
May, 2527---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024David DaiUBS$30.00$15.6192.18%353.17%
Aug 08, 2024Jeffrey HungMorgan Stanley$38.00$16.38131.99%474.02%
May 16, 2024Edward WhiteH.C. Wainwright$28.00$26.724.79%322.96%
Apr 17, 2024Kaveri PohlmanBTIG$30.00$17.3273.21%353.17%
Apr 16, 2024Edward WhiteH.C. Wainwright$29.00$17.6364.49%338.07%
Feb 03, 2023Morgan Stanley$19.00$11.9159.53%187.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025H.C. WainwrightBuyBuyhold
Oct 29, 2024BTIGBuyBuyhold
Oct 24, 2024UBSBuyinitialise
Oct 17, 2024H.C. WainwrightBuyBuyhold
Sep 18, 2024BTIGBuyBuyhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024William BlairOutperformOutperformhold
Aug 08, 2024Morgan StanleyOverweightOverweighthold
May 16, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.17$-1.47$-3.69-----
Avg Forecast$-2.04$-1.28$-4.09$-3.04$-3.10$-3.00$-2.33$-2.87
High Forecast$-1.42$-0.89$-4.05$-2.95$-2.51$-2.42$-0.05$-1.60
Low Forecast$-2.67$-1.67$-4.13$-3.33$-4.09$-4.65$-4.12$-4.14
Surprise %-42.65%14.84%-9.78%-----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$18.94M------
Avg Forecast$4.50M$18.91M-$1.67M$10.65M$33.02M$56.13M$58.02M
High Forecast$5.56M$23.38M-$2.24M$14.28M$33.16M$56.64M$77.82M
Low Forecast$3.44M$14.46M-$1.10M$7.02M$32.89M$55.62M$38.24M
Surprise %-0.15%------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-50.85M$-65.04M$-153.16M-----
Avg Forecast$-84.76M$-53.08M$-169.76M$-130.49M$-137.20M$-146.98M$-86.74M$-119.11M
High Forecast$-58.80M$-36.82M$-168.11M$-122.60M$-104.43M$-100.70M$-2.28M$-66.31M
Low Forecast$-110.75M$-69.35M$-171.42M$-138.38M$-169.96M$-193.27M$-171.21M$-171.96M
Surprise %-40.01%22.53%-9.78%-----

CGEM Forecast FAQ

Is Cullinan Therapeutics stock a buy?

Cullinan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cullinan Therapeutics is a favorable investment for most analysts.

What is Cullinan Therapeutics's price target?

Cullinan Therapeutics's price target, set by 8 Wall Street analysts, averages $31.5 over the next 12 months. The price target range spans from $28 at the low end to $38 at the high end, suggesting a potential 375.83% change from the previous closing price of $6.62.

How does Cullinan Therapeutics stock forecast compare to its benchmarks?

Cullinan Therapeutics's stock forecast shows a 375.83% upside, outperforming the average forecast for the healthcare stocks sector (13.55%).

What is the breakdown of analyst ratings for Cullinan Therapeutics over the past three months?

  • September 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cullinan Therapeutics’s EPS forecast?

Cullinan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.04, marking a -17.62% decrease from the reported $-3.69 in 2023. Estimates for the following years are $-3.1 in 2025, $-3 in 2026, $-2.33 in 2027, and $-2.87 in 2028.

What is Cullinan Therapeutics’s revenue forecast?

Cullinan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $1.67M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $10.65M, followed by $33.02M for 2026, $56.13M for 2027, and $58.02M for 2028.

What is Cullinan Therapeutics’s net income forecast?

Cullinan Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-130M, representing a -14.80% decrease from the reported $-153M in 2023. Projections indicate $-137M in 2025, $-147M in 2026, $-86.744M in 2027, and $-119M in 2028.